Latanoprost

Generic Name
Latanoprost
Brand Names
Iyuzeh, Rocklatan, Xalacom, Xalatan, Xelpros, Catiolanze
Drug Type
Small Molecule
Chemical Formula
C26H40O5
CAS Number
130209-82-4
Unique Ingredient Identifier
6Z5B6HVF6O
Background

Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment. It has been found to be well-tolerated and its use does not normally result in systemic adverse effects l...

Indication

Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension. It is available as monotherapy or in a combination product with netarsudil or timolol.
...

Associated Conditions
Increased Intra Ocular Pressure (IOP), Ocular Hypertension, Open Angle Glaucoma (OAG)
Associated Therapies
-
Clinical Trials
Related News

Efficacy Comparison of Xalatan and Azopt on POAG and OH

Not Applicable
Conditions
Ocular Hypertension
Interventions
Drug: Brinzolamide
Drug: Latanoprost
First Posted Date
2010-03-11
Last Posted Date
2010-03-11
Lead Sponsor
Peking University First Hospital
Target Recruit Count
130
Registration Number
NCT01084902

A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG

First Posted Date
2009-12-21
Last Posted Date
2014-01-10
Lead Sponsor
Mati Therapeutics Inc.
Target Recruit Count
15
Registration Number
NCT01037036
Locations
🇺🇸

Menlo Park, Menlo Park, California, United States

Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure

Phase 4
Completed
Conditions
Open Angle Glaucoma
Ocular Hypertension
Interventions
Drug: Latanoprost
First Posted Date
2009-07-17
Last Posted Date
2015-07-07
Lead Sponsor
Aristotle University Of Thessaloniki
Target Recruit Count
174
Registration Number
NCT00941525
Locations
🇬🇷

A' Department of Ophthalmology, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

First Posted Date
2009-07-08
Last Posted Date
2021-05-03
Lead Sponsor
Pfizer
Target Recruit Count
31
Registration Number
NCT00934089
Locations
🇺🇸

West Coast Clinical Trials, LLC, Cypress, California, United States

🇺🇸

Glory Medical Group, Garden Grove, California, United States

🇺🇸

Los Angeles Eye Medical Group, Los Angeles, California, United States

and more 4 locations

DuoTrav APS Versus XALACOM® in Ocular Surface Health

First Posted Date
2009-06-03
Last Posted Date
2012-07-19
Lead Sponsor
Alcon Research
Target Recruit Count
240
Registration Number
NCT00912054
Locations
🇧🇪

Cliniques Universitaires Saint Luc, Brussels, Belgium

Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure

Phase 4
Completed
Conditions
Glaucoma
Interventions
Drug: latanoprost
First Posted Date
2009-05-21
Last Posted Date
2015-08-18
Lead Sponsor
University of Sao Paulo
Target Recruit Count
56
Registration Number
NCT00906594
Locations
🇧🇷

University of Sao Paulo, Sao Paulo, SP, Brazil

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

Phase 1
Completed
Conditions
Glaucoma
Ocular Hypertension
Interventions
Drug: RKI983A
Drug: Latanoprost
First Posted Date
2009-02-19
Last Posted Date
2020-12-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
276
Registration Number
NCT00846989
Locations
🇺🇸

Novartis Investigative Site, Spokane, Washington, United States

A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)

Phase 2
Completed
Conditions
Open-Angle Glaucoma
Ocular Hypertension
Interventions
Drug: Latanoprost
First Posted Date
2009-01-12
Last Posted Date
2013-09-19
Lead Sponsor
Mati Therapeutics Inc.
Target Recruit Count
32
Registration Number
NCT00821002

Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.

Completed
Conditions
Glaucoma, Open-angle
Interventions
Drug: Xalacom
First Posted Date
2008-12-03
Last Posted Date
2021-02-18
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
457
Registration Number
NCT00801437
Locations
🇸🇰

Pfizer Investigational Site, Zvolen, Slovakia

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

Phase 4
Completed
Conditions
Dry Eye Disease
Interventions
Drug: Travatan Z
Drug: Xalatan
First Posted Date
2008-12-01
Last Posted Date
2011-07-21
Lead Sponsor
Ophthalmic Consultants of Long Island
Target Recruit Count
56
Registration Number
NCT00799682
Locations
🇺🇸

Ophthalmic Consultants of Long Island, Valley Stream, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy